How do we implement the next generation of precision medicines and therapies to optimise patient experience? We sat down with senior representatives from Novartis, Merus, Labcorp, and Simcere Pharmaceuticals to discover the latest industry insights.

Liquid biopsy has the potential to become a transformative cancer management and therapeutic strategy within the next 5 to 10 years. However, its capability across all cancer stages largely depends upon assay sensitivity. In this commentary piece, the University of Edinburgh’s Tim Aitman takes us through a novel approach set to pioneer the landscape of liquid biopsy.

With an increasing need for large data analysis and validation, this Insight article takes an in-depth look at some of the recent advances in automation technologies affecting the flow cytometry field.

How can the biomarkers industry best implement multi-parameter flow cytometry in clinical drug development? Vilma Decman of GlaxoSmithKline takes us through the advantages of using spectral flow cytometry, the importance of viability dyes, and high-parameter panel design.

Qing Kang-Fortner, Ph.D., Senior Scientist, Translational Medicine, Syros Pharmaceuticals, Inc

Steve Anderson, Senior Vice President, Chief Scientific Officer, Covance